Posco

Postech Academy-industry Foundation

Postech Foundation

Pohang University of Science and Technology Foundation

Dong-a University Research Foundation for Industry-academy Cooperation

Sung-Ho Ryu

Pann-Ghill Suh

Yoe-Sik Bae

Youn-Dong Kim

Jung-Hwan Lee

Hyun-Gu Kang

Tae-Hoon Lee

Sung-Key Jang

Jong-In Kim

Ji-Young Song

Do-Hyung Kim

Hye-Jung Lee

Hyun-Ju Lee

Mi-Nam Lee

Il-Shin Kim

Eun-Young Park

Sang-Hoon Ha

Sun-Hak Lee

Jong-Hun Im

Young-Chan Chae

Ki-Seok Kim

Eun-Jung Jang

Yoon-Keun Kim

Mi-Jin Kwon

Taehoon Lee

Jung-Kyu Park

Hyunjoo Bae

Sei-Kwang Hahn

Eun-Ju Oh

Young-Chul Sung

You-Suk Seo

Sang-Doo Kim

Dong-II Han

Jong Heon Kim

Bum-Su Park

Seung-Jin Lee

Jung-Hwan Kim

Soon-Hag Kim

Jong-Hyun Kim

Kyung-Moo Yea

Byoung-Dae Lee

Jae-Yoon Kim

The present invention relates to an immunoregulating agent comprising a peptide, a pharmaceutical composition and a method of preventing or treating immune-related disorder such as sever sepsis or acute respiratory distress syndrome (ARDS), and the use of peptide for anti-inflammatory agent, an antibacterial agent, or an inhibiting agent of an immune cell apoptosis.

Composition and method for preventing and treating immune-related disorder

The present invention provides methods for identifying the plurality of aptamers that bind to different sites of a target molecule and methods for using the same, for example, in sandwich assays. In particular, the plurality of aptamers binding to different sites of the target molecules is identified from a library of aptamers identified from the same SELEX process.

Aptamer sandwich assays

Improved G-rich oligonucleotide (GRO) aptamers specific to nucleolin, a method of preparing the aptamers, and a use of the aptamers for diagnosing and/or treating a nucleolin-associated disease, are provided.

Nucleolin specific aptamer and use thereof

The present invention relates to a method of regulating mammalian target-of-rapamycin (mTOR) by regulating a phospholipase D (PLD) activity that generates a complex with mTOR. Further, the present invention also relates to a method of screening inhibitors of mTOR, and a method and a composition for treating mTOR-related metabolic diseases by inhibiting mTOR.

Method of regulating mammalian target-of-rapamycin activity by interaction between phospholipase D and raptor

The invention relates to a long-acting formulation of biopharmaceutical, more specifically an aptamer therapeutics. A branched PEGylated aptamer or a hyaluronic acid (HA) derivative of which degradation in vivo is regulated is linked by the bioconjugation with biopharmaceutical to produce the long-action formulation.

Long acting formulation of biopharmaceutical

The present invention relates to method of regulating mammalian target-of-rapamycin (mTOR) based on a novel finding of a regulating mechanism of mTOR by a phospholipase D (PLD), and Ras homolog enriched in brain (Rheb). Further, the present invention also relates to a method of screening inhibitors of mTOR, and a method and a composition for treating mTOR-related metabolic diseases by inhibiting mTOR.

Method of regulating mammalian target-of-rapamycin activity by interaction between phospholipase D and Rheb

A method for preparing amino linker oligonucleotides is provided. More specifically, a method of preparing 5'-amino-linker oligonucleotides comprising the steps of: introducing an amino linker having a protecting group into the 5&#x2032; terminus of an oligonucleotide; and removing the protecting group from the amino linker oligonucleotide by contacting with acetic acid and 2,2,2-trifluoroethanol is provided. The amino protecting group is efficiently removed from the amino linker oligonucleotides, and thereby achieving a high yield of the amino linker oligonucleotides.

Method of preparing 5'-amino-linker oligonucleotides derivatives and analogous 5&#x2032;-labeled-linker oligonucleotides therefrom

Disclosed are peptides having SEQ ID NOs: 1 to 24 that induce superoxide generation by human monocytes or neutrophils; that induce an intracellular calcium increase by human peripheral blood monocytes or neutrophils; binds to formyl peptide receptor or formyl peptide receptor-like 1; that induce chemotactic migration of human monocytes or neutrophils in vitro; that induce degranulation in formyl peptide receptor expressing cells or formyl peptide receptor-like 1 expressing cells; that stimulate extracellular signal regulated protein kinase phosphorylation via activation of formyl peptide receptor or formyl peptide receptor-like 1; or that stimulate Akt phosphorylation via activation of formyl peptide receptor or formyl peptide receptor-like 1.

Immune-modulating peptide

The present application describes peptides that stimulate arachidonic acid release in target cells. The application also discloses peptides that cause intracellular calcium release. The application also discloses methods of using the disclosed peptides.

Leukocyte stimulating peptides

Disclosed are peptides having SEQ ID NOs: 1 to 32 that can stimulate superoxide generation in human monocytes. Superoxide is the most important armory on the primary defense line of monocytes against invading pathogens, and the identification of new stimuli and the characterization of the regulatory mechanism of superoxide generation are of paramount importance.

Immune-enhancing peptides

The present application describes peptides that stimulate arachidonic acid release in target cells. The application also discloses peptides that cause intracellular calcium release.

A vaccine having a good vaccination effect, which comprises an antigen; a peptide selected from the group consisting of a peptide having the amino acid sequence of SEQ ID NO: 1, a peptide having the amino acid sequence of SEQ ID NO: 2, and a peptide derived from a peptide having the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2; and an immune activator.

Vaccine composition containing a promoter peptide

Growing community of inventors

Pohang, South Korea

Sung-Ho Ryu